Stockreport

Longeveron Announces 2025 Full Year Financial Results and Provides Business Update

Longeveron Inc. - Class A Common stock  (LGVN) 
PDF On track for third quarter 2026 top-line trial results from anticipated pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatm [Read more]